Jared Tangney

And there's a couple areas of focus.

One is extending the duration of wear.

So, you know, the standard devices that are out there today are around 14 days.

So that's one area of focus is one on our wearable side, you know, improving the battery life, you know, updating our connectivity so that it's fully connected to the phone.

Yeah, the Gen 1 is five days.

Five days, okay.

But yeah, we've now been running studies out to seven and 10 days showing that the approach is viable for extended duration.

So now it's around building the system around it.

So updating the wearable hardware, which today is NFC.

So you scan to get any additional information under the app.

Okay.

For the insulin-using population, you have to have that Bluetooth connectivity so that, for example, in the middle of the night, if you need to be awoken, if you're hypoglycemic or something, you have to have that Bluetooth connectivity.

So that's something we're focusing on.

And then the third is you touched on manufacturing.

Really, before you can launch a product into the insulin-using population, you have to be at scale, right?

We can't say, hey, you've got type 1 diabetes.

You sign up to use a BioLink sensor, and a few months in, oh, hey, we're out of stock.

Sorry, we can't send you another sensor, right?

That's just a terrible experience.

That's really the next phase is scaling up manufacturing so we can meet that demand.